(19)
(11) EP 4 171 233 A1

(12)

(43) Date of publication:
03.05.2023 Bulletin 2023/18

(21) Application number: 21833175.9

(22) Date of filing: 28.06.2021
(51) International Patent Classification (IPC): 
A01N 43/04(2006.01)
A61K 39/395(2006.01)
A61K 31/675(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/496
(86) International application number:
PCT/US2021/039305
(87) International publication number:
WO 2022/005928 (06.01.2022 Gazette 2022/01)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 30.06.2020 US 202063046120 P
30.06.2020 US 202063046123 P

(71) Applicant: Imbria Pharmaceuticals, Inc.
Boston, MA 02110 (US)

(72) Inventors:
  • BUCKLEY, Neil
    Boston, MA 02116 (US)
  • BELMONT, Dan
    Boston, MA 02110 (US)
  • BETHUNE, Sarah
    Boston, MA 02110 (US)
  • DIAZ, Krista
    Boston, MA 02110 (US)
  • HAUSER, Bryan
    Boston, MA 02110 (US)
  • KIM, Myoung, Goo
    Boston, MA 02110 (US)
  • KANNAN, Kumar
    Boston, MA 02110 (US)

(74) Representative: HGF 
HGF Limited 1 City Walk
Leeds LS11 9DX
Leeds LS11 9DX (GB)

   


(54) CRYSTAL FORMS OF 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN -1-YL]ETHYL PYRIDINE-3-CARBOXYLATE AND METHODS OF SYNTHESIS